BridgeMD
New treatment option for Deprescriptions
Official title Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
ClinicalTrials.gov ID: NCT05842928
What this study is testing
- What it's testing
- The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag/medication review and patient empowerment, (4) GP practice visit with shared decision making.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Aged 65 years or older
- Patient is capable of giving consent
- GP contact in the quarter prior to inclusion
- Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic...
- Willingness to select a regular pharmacy for the study period
You likely can't join if
- Terminal illness (life expectancy \< 6 months)
- Current treatment of pain associated with cancer
- Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's...
- Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)
- Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy...
- Current participation in research projects on medication safety or geriatric medicine
See the full eligibility criteria
- Aged 65 years or older
- Patient is capable of giving consent
- GP contact in the quarter prior to inclusion
- Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months
- Willingness to select a regular pharmacy for the study period
- Consent to data exchange between GP and community pharmacy
- Terminal illness (life expectancy \< 6 months)
- Current treatment of pain associated with cancer
- Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)
- Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)
- Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity)
- Current participation in research projects on medication safety or geriatric medicine
The study team makes the final eligibility decision.
Where it's taking place
- Bielefeld, Germany
- Munich, Germany
- Witten, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bielefeld, Germany; Munich, Germany; Witten, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.